Global Endometriosis Drugs Market 2016-2020

2016-07-08
Price :
Published : Jul-2016
No. of Pages : 70

Endometriosis is a common health condition in women where the endometrial tissue, which is found in the lining of the uterus, appears and grows outside the uterine cavity. The endometrial tissue is shed from the body during menstruation.

The tissue growing outside the uterine cavity is called endometrial implants. Endometriosis can also occur in the fallopian tubes, ovaries, pelvic cavity, vagina, cervix, and bladder. In rare cases, it has been reported in other parts of the body such as the lungs, brain, and skin. These implants are usually benign in nature. Women of reproductive age are often affected by this condition.

Endometriosis often occurs due to retrograde menstruation, where the menstrual blood flows back into the pelvic cavity instead of leaving the body. This then adheres to the surface of the bladder, ovaries, or rectum and continues to grow or thicken over the course of each menstrual cycle.

The analysts forecast Global Endometriosis Drugs market to grow at a CAGR of 2.05% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the Global Endometriosis Drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

This report, Global Endometriosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • AstraZeneca
  • Bayer HealthCare
  • Pfizer

Other prominent vendors

  • Addex Therapeutics
  • Astellas Pharma
  • Debiopharm
  • ElexoPharm
  • Endoceutics
  • Euroscreen
  • Forendo Pharma
  • Isifer
  • Kissei Pharmaceutical
  • Neurocrine Biosciences
  • Nippon Shinyaku
  • ObsEva
  • Orphagen Pharmaceuticals
  • Philogen
  • PregLem
  • Repros Therapeutics
  • Roivant Sciences
  • SK Chemicals
  • Speciality European Pharma
  • SYNG Pharmaceuticals
  • Takeda
  • United Pharmaceuticals
  • ValiPharma

Market driver

  • Increased adoption of OCPs
  • For a full, detailed list, view our report

Market challenge

  • Surgeries as primary treatment option
  • For a full, detailed list, view our report

Market trend

  • Increased focus on intrauterine devices (IUDs)
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Growth Hormone Deficiency – Epidemiology Forecast to 2026

EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2026 Summary GHD is an endocrine disorder characterized by the insufficient production of GH by the pituitary gland (CGF, 2003). The ICD-10 Clinical Modification (ICD-10-CM) code for GHD is E23.0. GHD is more commonly seen in children, although it can develop during adulthood. GHD can be present from birth, in which case it is known as congenital, or it can be secondary due to brain trauma and is known as acquired. The signs and symptoms of the disease can vary. Generally, a child with GHD is born with normal size at birth, but has delayed rates of bone development and bone lengthening later on. GHD in children affects growth and development. In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes ......
$3995

EpiCast Report: Venous Thromboembolism – Epidemiology Forecast to 2026

EpiCast Report: Venous Thromboembolism - Epidemiology Forecast to 2026 Summary Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE (AHA, 2017). Our epidemiologists forecast an increase in the diagnosed inciden......
$3995

Chlamydia Tests – Medical Devices Pipeline Assessment, 2017

Chlamydia Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, "Chlamydia Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Chlamydia Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Chlamydia Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team o......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the......
$3500

Bordetella pertussis Infections Global Clinical Trials Review, H1, 2017

Bordetella pertussis Infections Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bordetella pertussis Infections Global Clinical Trials Review, H1, 2017" provides an overview of Bordetella pertussis Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Bordetella pertussis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500

Bronchiolitis Global Clinical Trials Review, H1, 2017

Bronchiolitis Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bronchiolitis Global Clinical Trials Review, H1, 2017" provides an overview of Bronchiolitis clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchiolitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Cachexia Global Clinical Trials Review, H1, 2017

Cachexia Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Cachexia Global Clinical Trials Review, H1, 2017" provides an overview of Cachexia clinical trials scenario. This report provides top line data relating to the clinical trials on Cachexia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated......
$2500

Botulism Global Clinical Trials Review, H1, 2017

Botulism Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Botulism Global Clinical Trials Review, H1, 2017" provides an overview of Botulism clinical trials scenario. This report provides top line data relating to the clinical trials on Botulism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated......
$2500

Bronchiolitis Obliterans Global Clinical Trials Review, H1, 2017

Bronchiolitis Obliterans Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Bronchiolitis Obliterans Global Clinical Trials Review, H1, 2017" provides an overview of Bronchiolitis Obliterans clinical trials scenario. This report provides top line data relating to the clinical trials on Bronchiolitis Obliterans. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Cancer Anorexia-Cachexia Syndrome Global Clinical Trials Review, H1, 2017

Cancer Anorexia-Cachexia Syndrome Global Clinical Trials Review, H1, 2017 Summary GlobalData's clinical trial report, "Cancer Anorexia-Cachexia Syndrome Global Clinical Trials Review, H1, 2017" provides an overview of Cancer Anorexia-Cachexia Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using Glob......
$2500